RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cells
Triple-negative breast cancer (TNBC) stands out as the most aggressive subtype within the spectrum of breast cancer. The current clinical guidelines propose treatment strategies involving cytotoxic agents like epirubicin or paclitaxel. However, the emergence of acquired resistance frequently precipi...
Үндсэн зохиолчид: | Fengxu Lv, Wentao Si, Xiaodan Xu, Xiaogang He, Ying Wang, Yetian Li, Feifei Li |
---|---|
Формат: | Өгүүллэг |
Хэл сонгох: | English |
Хэвлэсэн: |
Elsevier
2024-02-01
|
Цуврал: | Neoplasia: An International Journal for Oncology Research |
Нөхцлүүд: | |
Онлайн хандалт: | http://www.sciencedirect.com/science/article/pii/S1476558624000046 |
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
RUNX2 facilitates aggressiveness and chemoresistance of triple negative breast cancer cells via activating MMP1
-н: Wentao Si, зэрэг
Хэвлэсэн: (2022-11-01) -
RUNX1 Is Regulated by Androgen Receptor to Promote Cancer Stem Markers and Chemotherapy Resistance in Triple Negative Breast Cancer
-н: Natalia B. Fernández, зэрэг
Хэвлэсэн: (2023-01-01) -
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers
-н: Bradley A. Hancock, зэрэг
Хэвлэсэн: (2019-08-01) -
Comprehensive Analysis of RUNX and TGF-β Mediated Regulation of Immune Cell Infiltration in Breast Cancer
-н: Liang Gao, зэрэг
Хэвлэсэн: (2021-08-01) -
TGF-β induced reprogramming and drug resistance in triple-negative breast cells
-н: Guoyu Wu, зэрэг
Хэвлэсэн: (2022-04-01)